Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The most promising chimeric natriuretic peptide designed and studied by our group has been
CD-NP which has anti-fibrotic and cardioprotective properties in vivo, vitro and in normal
volunteers and human heart failure patients. Since left ventricular assist device (LVAD) can
not reverse remodeling of the heart whereas it can improve hemodynamics, CD-NP may be novel
anti-fibrotic and anti-remodeling drug as co-therapy during LVAD support.